Tsingke's Innovative Approaches for Advancing Antibody Candidates at PEGS Europe 2026

Tsingke's Insights on Antibody Candidate Advancement at PEGS Europe 2026



During the recent PEGS Europe 2026 held in Lisbon, Tsingke showcased their expertise in guiding biotechnology teams through the crucial stages of antibody drug development. With a strong focus on turning early antibody candidates into viable therapeutic options, Tsingke aims to streamline the decision-making process for R&D teams.

Understanding Antibody Candidates


An effective drug discovery journey begins with identifying an antibody that binds its target. However, the next steps are crucial: determining which candidates can be synthesized, which maintain their specific binding characteristics when modified, and which candidates deserve further investment. Tsingke’s comprehensive workflow integrates key phases such as antibody discovery, recombinant expression, engineering, and detailed characterization to answer these pivotal questions.

From Early Discovery to Advanced Selection


At PEGS Europe 2026, Tsingke emphasized the importance of evaluating which early antibody hits are worth advancing. For teams initiating their projects with immune samples or hybridoma clones, the services offered by Tsingke assist in transforming a list of potential candidates into a set of recombinant antibodies suitable for side-by-side comparison. Tsingke employs a unique single B-cell screening workflow that effectively preserves the natural pairing of heavy and light chains. Additionally, hybridoma sequencing provides teams with a viable pathway for retrieving sequences from existing clones, facilitating a smoother transition into the next development stage.

Once recombinant candidates are expressed, teams can utilize binding assays to analyze their interactions. Techniques such as cell-based binding via flow cytometry, along with binding kinetics measured by Biolayer Interferometry (BLI) or Surface Plasmon Resonance (SPR), provide essential data on which candidates to prioritize for additional testing.

Evaluating Antibody Property Retention


Another critical aspect of antibody development is assessing whether a candidate retains its desired properties when transitioned to different formats, such as Fab or scFv. Tsingke’s methodology encourages teams to conduct comparative studies of these formats through recombinant expression and binding characterization. For programs necessitating distinct binding behavior across varying pH levels, Tsingke offers specialized pH-dependent screening and engineering services, with characterization specifically catered to each program's goals.

The Role of Antibody-Oligonucleotide Conjugates


The evaluation of antibody–oligonucleotide conjugates (AOCs) marks a significant decision-making juncture for many teams. It is imperative to have a well-characterized sample for follow-up studies to inform next steps effectively. Tsingke excels in providing comprehensive solutions that integrate antibody production, oligonucleotide synthesis, conjugation, purification, and thorough LC-MS characterization. This holistic approach ensures that teams obtain critical analytical data necessary for assessing the conjugated materials and for selecting appropriate samples for further functional assessments.

The Tsingke Promise


As highlighted by Yuan Wu, Tsingke’s International BD Manager, “Every team approaches us at different stages of their development journey. Some are equipped with early antibody hits and are in search of reliable comparative methods, while others possess a lead and need insight into how alterations in format or conjugation might impact their molecules.” Tsingke fundamentally aligns its production and characterization efforts with the teams’ specific decision-making needs.

About Tsingke


Beijing Tsingke Biotech Co., Ltd. stands at the forefront of molecular biology and biologics, delivering a wide array of research services tailored for pharmaceutical, biotechnology, and academic teams. These services encompass custom DNA and RNA synthesis, antibody discovery, recombinant protein production, antibody engineering, and detailed analytical characterization. For further updates and insights, follow Tsingke Biotech on LinkedIn.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.